- Golden Age of Immunotherapy: Challenges and Opportunities
-
Chung Y, Lee SW, Kim WU
- KMID: 2536232
- Immune Netw.
- 2022 Feb;22(1):e1.
- doi: 10.4110/in.2022.22.e1
-
- CITED
-
- Close
- SHARE
-
- Close
- Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
-
Lee JB, Kim HR, Ha SJ
- KMID: 2536233
- Immune Netw.
- 2022 Feb;22(1):e2.
- doi: 10.4110/in.2022.22.e2
Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved in 2011 for treatment of metastatic melanoma, eight immune checkpoint... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases
-
Park Y, Kwok SK
- KMID: 2536228
- Immune Netw.
- 2022 Feb;22(1):e10.
- doi: 10.4110/in.2022.22.e10
Systemic autoimmune diseases arise from loss of self-tolerance and immune homeostasis between effector and regulator functions. There are many therapeutic modalities for autoimmune diseases ranging from conventional disease-modifying anti-rheumatic drugs... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of T Cells in Obesity-Associated Inflammation and Metabolic Disease
-
Park CS, Shastri N
- KMID: 2536231
- Immune Netw.
- 2022 Feb;22(1):e13.
- doi: 10.4110/in.2022.22.e13
Chronic inflammation plays a critical role in the development of obesity-associated metabolic disorders such as insulin resistance. Obesity alters the microenvironment of adipose tissue and the intestines from anti-inflammatory to... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeted Immunotherapy for Autoimmune Disease
-
Jung SM, Kim WU
- KMID: 2536240
- Immune Netw.
- 2022 Feb;22(1):e9.
- doi: 10.4110/in.2022.22.e9
In the past few decades, biological drugs and small molecule inhibitors targeting inflammatory cytokines, immune cells, and intracellular kinases have become the standard-of-care to treat autoimmune diseases. Inhibition of TNF,... -
- CITED
-
- Close
- SHARE
-
- Close
- Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research
-
Kim M, Choe Yh, Lee Si
- KMID: 2536239
- Immune Netw.
- 2022 Feb;22(1):e8.
- doi: 10.4110/in.2022.22.e8
Rheumatoid arthritis (RA) is a representative autoimmune disease that is primarily characterized by persistent inflammation and progressive destruction of synovial joints. RA has a complex and heterogeneous pathophysiology, involving interactions... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
-
Song A, Lee SE, Kim JH
- KMID: 2536238
- Immune Netw.
- 2022 Feb;22(1):e7.
- doi: 10.4110/in.2022.22.e7
Recently, there have been impressive advancements in understanding of the immune mechanisms underlying cutaneous inflammatory diseases. To understand these diseases on a deeper level and clarify the therapeutic targets more... -
- CITED
-
- Close
- SHARE
-
- Close
- Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy
-
Bae J, Park K, Kim YM
- KMID: 2536234
- Immune Netw.
- 2022 Feb;22(1):e3.
- doi: 10.4110/in.2022.22.e3
Cancer is one of the leading causes of death worldwide and the number of cancer patients is expected to continuously increase in the future. Traditional cancer therapies focus on inhibiting... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review
-
Lee SP, Shin YS, Kang SY, Kim TB, Lee SM
- KMID: 2536230
- Immune Netw.
- 2022 Feb;22(1):e12.
- doi: 10.4110/in.2022.22.e12
Allergen-specific immunotherapy (AIT) is presumed to modulate the natural course of allergic disease by inducing immune tolerance. However, conventional AITs, such as subcutaneous immunotherapy and sublingual immunotherapy, require long treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- CAR T Cell Immunotherapy Beyond Haematological Malignancy
-
Hupperetz C, Lah S, Kim H, Kim CH
- KMID: 2536237
- Immune Netw.
- 2022 Feb;22(1):e6.
- doi: 10.4110/in.2022.22.e6
Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies. However, their transition beyond haematological malignancy... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside
-
Ham J, Shin JW, Ko BC, Kim HY
- KMID: 2536229
- Immune Netw.
- 2022 Feb;22(1):e11.
- doi: 10.4110/in.2022.22.e11
When epithelial cells are exposed to potentially threatening external stimuli such as allergens, bacteria, viruses, and helminths, they instantly produce “alarmin” cytokines, namely, IL-33, IL-25, and TSLP. These alarmins alert... -
- CITED
-
- Close
- SHARE
-
- Close
- Advancements of Common GammaChain Family Cytokines in Cancer Immunotherapy
-
Wolfarth AA, Dhar S, Goon JB, Ezeanya UI, Ferrando-Martínez S, Lee BH
- KMID: 2536236
- Immune Netw.
- 2022 Feb;22(1):e5.
- doi: 10.4110/in.2022.22.e5
The approval of immunotherapies such as checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines has revolutionized the way cancer treatment is approached. While immunotherapies have improved clinical outcome in a... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
-
Moon D, Tae N, Park Y, Lee SW, Kim DH
- KMID: 2536235
- Immune Netw.
- 2022 Feb;22(1):e4.
- doi: 10.4110/in.2022.22.e4
In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab engineering, have provided multiple new candidates as therapeutic immunooncology modalities. Bispecific Abs (BsAbs) that recognize... -
- CITED
-
- Close
- SHARE
-
- Close
